So you say that the drug works better with Margolis 2 patients than Margolis 1 patients.Interesting and in this case we got things wrong, as we diverged on this assumption that our target was Margolis 1 instead of Margolis 2.
So we diverged among the two data trials and we lost a comparable apple to apple scenario. On the other side the placebo Margolis 1 group in the USA responded very good, probably because they were not so grave and complicated as the original European group. In Europe the patients were not responding to standard care for more than 3 years and they were extremely old (average 74 years old). But they healed substantially.
